Match!
Hayden Holmes
University of York
Physical therapyInflammatory bowel diseaseIrritable bowel syndromeFaecal calprotectinHealth economics
7Publications
2H-index
14Citations
What is this?
Publications 6
Newest
#1Amy Dymond (Ebor: University of York)H-Index: 1
#2Hayden Holmes (Ebor: University of York)H-Index: 2
view all 7 authors...
BACKGROUND: Local oestrogens, the current treatment for vulvar and vaginal atrophy (VVA), are not suitable for all women. Standard of care (SoC) consists of over-the-counter lubricants and moisturisers. Senshio((R)) (ospemifene) provides a treatment option for postmenopausal women who are not candidates for local vaginal oestrogen therapy who would otherwise have an unmet clinical need. OBJECTIVES: The aim of this study was to estimate the cost-effectiveness of ospemifene, a selective oestrogen ...
Source
#1Hayden HolmesH-Index: 2
#2Jessica McMasterH-Index: 1
Last. James Turvill (York Hospital)H-Index: 6
view all 5 authors...
Background: Lower gastrointestinal symptoms are common in the general population and it can be difficult to discriminate between inflammatory bowel disease (IBS) and irritable bowel syndrome (IBD) due to overlap of symptoms. The York Faecal Calprotectin Care Pathway (YFCCP) was introduced in 2016 as an alternative to the NICE faecal calprotectin pathway (DG11). This analysis uses the prospective data from the first 1005 patients in the YFCCP. Previous analysis demonstrated the YFCCP may be cost-...
Source
#2Ada Keding (Ebor: University of York)H-Index: 5
Last. James TurvillH-Index: 6
view all 5 authors...
Faecal calprotectin (FC) and the faecal immunochemical test for haemoglobin (FIT) are recommended for use in primary care where colorectal cancer (CRC) is not suspected.1 2 We are unclear how best to use these two biomarkers in younger patients where lower gastrointestinal symptoms are extremely common. Distinguishing irritable bowel syndrome from inflammatory bowel disease (IBD) from CRC on clinical grounds is often an uncertain exercise. Currently, there is no direct comparative evidence base ...
Source
Source
#1Amy DymondH-Index: 1
Last. R. Perard
view all 5 authors...
Source
#1James Turvill (York Hospital)H-Index: 6
#2Daniel TurnockH-Index: 5
Last. Stacey MarriottH-Index: 1
view all 7 authors...
Objective To evaluate the sensitivity and specificity of the York Faecal Calprotectin Care Pathway (YFCCP) and undertake a health economics analysis. The YFCCP has been introduced in support of the National Institute for Health and Care Excellence (NICE) guidance DG11. It is designed to improve the sensitivity and specificity of faecal calprotectin (FC) in discriminating the irritable bowel syndrome from inflammatory bowel disease in primary care. Design To prospectively evaluate the clinical ou...
3 CitationsSource
1